Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Holding(s) in Company

22 Jan 2009 13:00

RNS Number : 0964M
Hutchison China Meditech Limited
22 January 2009
 



TR-1: notification of major interests in shares 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

HUTCHISON CHINA MEDITECH LTD 

2. Reason for the notification   (please tick the appropriate box or boxes)

An acquisition or disposal of voting rights 

Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

No

An event changing the breakdown of voting rights

No

Other (please specify):

No

3. Full name of person(s) subject to the notification obligation:

UBS Investment Bank

4. Full name of shareholder(s) (if different from 3.):

UBS AG

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

19 January 2009

6. Date on which issuer notified:

21 January 2009

7. Threshold(s) that is/are crossed or reached:

3.90%

8. Notified details:

A: Voting rights attached to shares

Class/type of shares 

if possible using the ISIN CODE

Situation previous to the Triggering transaction

Resulting situation after the triggering transaction

Number of Shares 

Number of Voting Rights

Number of shares

 

Number of voting rights 

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

KYG4672N1016

No Previous Disclosure

No Previous Disclosure

2,000,000

2,000,000

-

3.90%

-

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument 

Expiration date

Exercise/ Conversion Period/ Date

Number of voting rights that may be acquired if the instrument is exercised/ converted. 

% of voting rights

-

-

-

-

-

Total (A+B)

Number of voting rights

% of voting rights

2,000,000

3.90%

  

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

-

Proxy Voting:

10. Name of the proxy holder:

-

11. Number of voting rights proxy holder will cease to hold:

-

12. Date on which proxy holder will cease to hold voting rights:

-

13. Additional information:

14. Contact name:

Cintia Goertz / Sarah Cottle

UBS AG

15. Contact telephone number:

0207 568 4981

For notes on how to complete form TR-1 please see the FSA website.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUVURKKRAUAR
Date   Source Headline
5th Jun 20269:30 amRNSBlock Admission Application
22nd May 20267:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
21st May 202611:00 amRNS-RNMPA approval for ELUNATE with TYVYT
12th May 202612:45 pmRNSAnnouncement on Results of Annual General Meeting
30th Apr 20269:30 amRNSTotal Voting Rights
29th Apr 202611:00 amRNS-RHUTCHMED Announces NDA Acceptance in China
9th Apr 20269:30 amRNS2025 Annual Report and Notice of AGM
9th Apr 20267:00 amRNS-RData to be Presented at AACR Annual Meeting 2026
23rd Mar 20267:00 amRNS-RHUTCHMED Initiates Phase III Trial of HMPL-760
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
9th Mar 20269:30 amRNSUpdate on Licensed Oncology Product in China
6th Mar 20268:30 amRNSDirectorate change
5th Mar 20261:00 pmRNS-RPublication of Form 20-F
5th Mar 202611:00 amRNS2025 Full Year Results and Business Updates
4th Mar 20268:30 amRNS-RHUTCHMED Initiates Global Trial of ATTC Candidate
6th Feb 20268:30 amRNSHUTCHMED to Announce 2025 Final Results
14th Jan 20267:00 amRNS-RPublication of Phase III Results in The Lancet
7th Jan 20267:00 amRNS-RPositive Topline Results of Phase III Trial
5th Jan 20267:00 amRNS-RSurufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
17th Dec 20257:00 amRNS-RHUTCHMED Initiates Development of ATTC Candidate
8th Dec 20257:00 amRNSExpanded NRDL Coverage + CIDL Inclusion in China
28th Nov 20258:30 amRNSTotal Voting Rights
27th Nov 20257:00 amRNS-RHUTCHMED Highlights Data at ESMO and ASH
5th Nov 20257:00 amRNS-REnrollment Complete in SAFFRON Global Phase III
3rd Nov 20257:00 amRNS-RUpdates from R&D Event
23rd Oct 20257:00 amRNS-RHUTCHMED Presents Data at AACR NCI EORTC
21st Oct 20259:30 amRNSVesting of awards under Long Term Incentive Plan
14th Oct 20259:30 amRNSAppointment of Independent Non-executive Director
13th Oct 20257:05 amRNS-RData to be Presented at the 2025 ESMO Congress
2nd Oct 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ESMO
30th Sep 20259:30 amRNSTotal Voting Rights
12th Sep 20257:00 amRNS-RHUTCHMED to Present R&D Updates on October 31 2025
5th Sep 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at CSCO
26th Aug 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase III Trial
7th Aug 202512:00 pmRNS2025 Interim Results
3rd Jul 20259:30 amRNSHUTCHMED to Announce 2025 Half-Year Results
2nd Jul 202510:00 amRNSUpdate on Joint Corporate Brokers in London
30th Jun 20259:30 amRNSChina Approval based on Phase III SACHI Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.